Todd Harrison says the cracks in DSHEA gaped a bit wider last month with the FTC’s proposed consent decree limiting claims by iHealth and Martek Biosciences for the BrainStrong Adult cognitive function supplement. The decree is a “shot through the heart” of the supplement industry, says Harrison, partner in Venable, a Washington D.C. law firm, and he worries whether the industry can mount the sort of response needed.
Recent FTC ruling discourages supplement research, Washington lawyer says
A proposed FTC consent decree finds that a study for BrainStrong was not sufficient to make congitive claims. Venable partner Todd Harrison says the high standard discourages research.